Although the research towards the development of small molecules as proteasome activators is scarce, the results so far suggest that activation of the proteasome complex constitutes a pioneer strategy for the deceleration of ageing and age-related diseases A novel class of hybrid compounds that combine structural features of benzothiophene and of hydroxytyrosol connected through carefully selected linkers, was designed and synthesized by our group, leading to the development of an optimum structural proteasome activator.
STHENOS-b 2017-2020 in collaboration with members of other research groups of I.C.B.
This class of compounds was further exploited by synthesizing more analogues. The biological results to date show great promise with regards to the anti-ageing and neuroprotective effects of the new analogues in cellulo and in organismal level.
RESET: “Bio-inspired antiaging proteasome activators” In collaboration with Intermed SA.